Wordt geladen...
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...
Bewaard in:
| Gepubliceerd in: | Drugs Context |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioExcel Publishing Ltd
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916097/ https://ncbi.nlm.nih.gov/pubmed/29707029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212518 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|